Stelac Advisory Services LLC Buys 22,806 Shares of Abbott Laboratories $ABT

Stelac Advisory Services LLC acquired a new stake in Abbott Laboratories (NYSE:ABT – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,806 shares of the healthcare product maker’s stock, valued at approximately $2,323,000.

A number of other large investors also recently bought and sold shares of the stock. Manning & Napier Advisors LLC acquired a new stake in shares of Abbott Laboratories during the second quarter valued at about $31,000. Foresight Capital Management Advisors Inc. acquired a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $31,000. Balance Wealth Partners LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $34,000. Summit Securities Group LLC boosted its position in shares of Abbott Laboratories by 41.3% during the 2nd quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock worth $37,000 after purchasing an additional 118 shares during the period. Finally, Addison Advisors LLC acquired a new stake in Abbott Laboratories in the 2nd quarter valued at approximately $40,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research analyst reports. TD Cowen cut their target price on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Argus cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Citigroup dropped their price objective on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Barclays initiated coverage on Abbott Laboratories in a report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 target price on the stock. Finally, Robert W. Baird raised their price target on Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research note on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $118.32.

Check Out Our Latest Report on Abbott Laboratories

Insider Buying and Selling

In related news, EVP Mary Moreland sold 3,500 shares of Abbott Laboratories stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the sale, the executive vice president directly owned 100,791 shares in the company, valued at $11,691,756. This trade represents a 3.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Performance

Shares of ABT opened at $104.64 on Wednesday. The stock has a 50 day moving average price of $103.89 and a 200 day moving average price of $101.74. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $181.23 billion, a price-to-earnings ratio of 39.04, a price-to-earnings-growth ratio of 1.88 and a beta of 0.54. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the company earned $1.30 earnings per share. Research analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, November 16th. Investors of record on Thursday, October 15th were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Read More

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.